Dual GLP-1 / GIP agonist

TerzaPowertirzepatide · 10 mg

Dual GLP-1/GIP receptor agonist for comprehensive weight management, metabolic balance, and glycemic control

GLP-1 + GIP −22,5% weight 1×/week

Request product Mechanism

Tirzepatide 10 mg Dual GLP-1/GIP agonism Subcutaneous, once weekly

Mechanism

Two receptors — one molecule

GLP-1

Appetite & satiety

Suppresses glucagon, slows gastric emptying and curbs appetite via central mechanisms.

−0%

SURMOUNT-1 · 72 weeks · 15 mg

GIP

Insulin & sensitivity

Boosts insulin secretion by beta cells and improves tissue insulin sensitivity.

Evidence

Backed by trials

SURMOUNT-1

Weight loss up to 22.5% over 72 weeks in obese patients (15 mg dose)

SURPASS-2

Superiority over semaglutide 1 mg in reducing HbA1c and body weight in type 2 diabetes

Dual mechanism

The only molecule with dual GLP-1/GIP agonism for maximum metabolic effect

FDA & EMA

FDA-approved (Mounjaro/Zepbound) for obesity and type 2 diabetes treatment

Effects

Key effects

Comprehensive metabolic impact through a dual mechanism of action

Weight loss up to 20%+

Glycemic control

Appetite reduction

Lipid profile improvement

Cardiometabolic protection

Insulin sensitivity

Blood pressure reduction

Sleep quality & energy levels

How it works

How TerzaPower

Dual activation of GLP-1 and GIP receptors in the GI tract and brain
Appetite and hunger reduction through central CNS mechanisms
Slowing of gastric emptying — prolonged satiety
Improvement of glucose-dependent insulin secretion by pancreatic beta cells
Reduction of glucagon production and suppression of hepatic gluconeogenesis
Activation of adipose tissue lipolysis and increased peripheral insulin sensitivity

Why TerzaPower?

How does TerzaPower differ from other GLP-1 agonists?

Unlike GLP-1 monotherapy (semaglutide, liraglutide), TerzaPower simultaneously activates GLP-1 and GIP receptors — two independent metabolic pathways. This provides greater weight loss efficacy (up to 22.5% in clinical trials) and better glycemic control compared to monotherapy.

Which patients is TerzaPower suitable for?

TerzaPower is suitable for adult patients with:

Obesity or overweight (BMI ≥ 27) with comorbid metabolic disorders
Type 2 diabetes requiring improved glycemic control
Elevated cardiometabolic risk
Metabolic syndrome as part of comprehensive therapy

Prescribing is exclusively by physician indication.

What clinical studies confirm efficacy?

SURMOUNT-1 — weight loss up to 22.5% over 72 weeks in obese patients without diabetes (15 mg dose).

SURPASS-2 — tirzepatide's superiority over semaglutide 1 mg in reducing HbA1c and body weight in type 2 diabetes patients.

SURMOUNT-4 — maintenance of results with long-term use; discontinuation leads to weight regain.

How to integrate TerzaPower into a wellness program?

TerzaPower is most effective in combination with:

Individual dietary protocol
Regular physical activity
Monitoring of metabolic indicators (glucose, lipids, BP)
Psychological support for changing eating behaviour

Titration protocol and duration of use are determined individually by the physician.

What are the side effects and contraindications?

Most common side effects (primarily during titration): nausea, vomiting, diarrhoea, decreased appetite — generally transient and managed by titration pace.

Contraindications: personal or family history of medullary thyroid carcinoma, MEN 2, pregnancy. Full list in the product information leaflet.

TrueMed Ukraine

Request TerzaPower 10 mg

Leave your details — a manager will contact you about terms, availability and partnership.

For professional use only, under the supervision of a qualified specialist. This information is not a public offer or a substitute for medical advice.